Firebrick Pharma Limited (AU:FRE)
ASX:FRE
Top Page
Firebrick Pharma Limited
(Sydney:FRE)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.06
▲(14.00% Upside)
Action:UpgradedDate:12/30/25
The score is driven primarily by weak financial performance (sharp revenue decline, persistent large losses, and ongoing negative free cash flow). Technical indicators also point to a sustained downtrend with negative momentum. The balance sheet is a mitigating factor due to zero reported debt, but losses and cash burn remain the dominant risks.
Positive Factors
Low leverage / balance sheet strength
Zero reported debt is a durable financial strength: it reduces insolvency risk, preserves borrowing capacity, and gives management flexibility to pursue licensing, commercialization or R&D without immediate debt servicing. This lowers fixed financial burdens and supports capital strategy over months ahead.
Negative Factors
Sharp revenue collapse
A ~74% year-over-year revenue decline signals material loss of commercial traction or distribution. Such a severe drop undermines the scalability of fixed-cost investments, damages negotiating leverage with partners, and raises the probability that management must materially restructure operations or seek dilutive financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / balance sheet strength
Zero reported debt is a durable financial strength: it reduces insolvency risk, preserves borrowing capacity, and gives management flexibility to pursue licensing, commercialization or R&D without immediate debt servicing. This lowers fixed financial burdens and supports capital strategy over months ahead.
Read all positive factors
Firebrick Pharma Limited (FRE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$13.63M
Dividend YieldN/A
Average Volume (3M)91.61K
Price to Earnings (P/E)―
Beta (1Y)-1.69
Revenue Growth1920.53%
EPS Growth-89.39%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,479,080
10 Day Avg. Volume136,612
30 Day Avg. Volume91,607
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)8.38
Price to Sales (P/S)44.43
P/FCF Ratio-7.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firebrick Pharma Limited Business Overview & Revenue Model
Company Description
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia....
How the Company Makes Money
null...
Firebrick Pharma Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 381.71K | 293.42K | 14.52K | 830.00 | 4.12K | 422.00K |
| Gross Profit | -260.68K | 104.82K | -22.78K | 830.00 | 4.12K | 421.48K |
| EBITDA | -2.45M | -2.86M | -1.17M | -6.81M | -4.86M | -2.86M |
| Net Income | -2.45M | -2.63M | -1.18M | -6.80M | -3.80M | -2.44M |
Balance Sheet | ||||||
| Total Assets | 2.28M | 1.83M | 2.41M | 2.98M | 8.73M | 11.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 983.35K | 824.78K | 2.35M | 7.14M | 11.16M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 341.73K | 271.28K | 291.07K | 506.44K | 450.10K | 214.80K |
| Stockholders Equity | 1.94M | 1.56M | 2.12M | 2.48M | 8.28M | 11.55M |
Cash Flow | ||||||
| Free Cash Flow | -2.25M | -1.86M | -2.35M | -5.78M | -4.23M | -1.95M |
| Operating Cash Flow | -2.24M | -1.78M | -2.34M | -5.78M | -4.20M | -1.94M |
| Investing Cash Flow | -16.50K | -82.98K | -134.00 | -1.62K | -32.54K | -16.07K |
| Financing Cash Flow | 2.78M | 2.02M | 815.21K | 996.65K | 10.23M | 3.01M |
Firebrick Pharma Limited Technical Analysis
Negative
0.05
Price Trends
0.06
Negative
0.06
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
30.78
Neutral
-22.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:FRE, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 30.78 is Neutral, neither overbought nor oversold. The STOCH value of -22.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:FRE.
Firebrick Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$88.72M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | AU$13.63M | -2.55 | -140.26% | ― | 1920.53% | -89.39% | |
42 Neutral | AU$82.09M | -14.80 | -40.65% | ― | 700.00% | 26.88% | |
41 Neutral | AU$133.02M | -2.84 | 279.21% | ― | ― | 0.66% | |
40 Underperform | AU$2.17M | -4.31 | -32.19% | ― | ― | 46.43% | |
38 Underperform | AU$45.75M | -3.02 | -37.14% | ― | 2.33% | 12.50% |
* Healthcare Sector Average
AU:FRE
Firebrick Pharma Limited
0.05
-0.04
-40.66%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.42
-91.21%
AU:RCE
Recce Pharmaceuticals Ltd.
0.46
0.10
29.21%
AU:ALA
Arovella Therapeutics Limited
0.07
-0.01
-15.00%
AU:IIQ
Inoviq Ltd
0.33
-0.08
-18.75%
Firebrick Pharma Limited Corporate Events
Firebrick Pharma Raises $1.5m to Fund Nasodine Expansion and New Products
Mar 31, 2026
Firebrick Pharma Limited has raised approximately $1.5 million through a share placement of about 31.9 million new shares at $0.047 each, representing roughly 12.6% of existing shares on issue and offered at a discount to recent trading prices. Th...
Firebrick Pharma Seeks ASX Trading Halt Ahead of Placement Announcement
Mar 26, 2026
Firebrick Pharma Limited has requested an immediate trading halt in its securities on the ASX while it prepares an announcement regarding a proposed placement. Trading in FRE shares will remain halted until the placement announcement is released o...
Firebrick Pharma Wins First Nasodine Approval in Major Indonesian Market
Mar 26, 2026
Firebrick Pharma has secured its first regulatory approval for Nasodine Nasal Spray in Indonesia, where the product has been classified as an antiseptic under the Household Health Supplies category, permitting immediate importation and marketing. ...
Firebrick Pharma to Showcase Nasodine Growth Strategy at NWR Virtual Healthcare Conference
Mar 18, 2026
Firebrick Pharma Limited will present at the NWR Virtual Healthcare Conference, with Executive Chair Dr Peter Molloy scheduled to speak in a live online session on 26 March 2026, followed by a recorded replay available via the conference link, com...
Firebrick Pharma Secures Philippine Patent for Nasodine COVID-19 Use
Mar 17, 2026
Firebrick Pharma has secured acceptance of a key patent in the Philippines covering the use of its Nasodine Nasal Spray and other intranasal povidone-iodine products to reduce SARS-CoV-2 viral load and provide pre-exposure prophylaxis against COVI...
Firebrick Pharma hires veteran dealmaker to spearhead global Nasodine expansion
Mar 16, 2026
Firebrick Pharma has appointed seasoned pharmaceutical licensing executive Nilesh Wadhwa as Head of Business Development and Licensing, following an international search for a specialist to accelerate its partnering strategy. Wadhwa brings around ...
Firebrick Pharma targets global expansion as Nasodine sales surge in U.S. and Asia
Mar 3, 2026
Firebrick Pharma has reported strong momentum for its Nasodine portfolio, highlighting robust sales growth in the U.S. and Singapore and signalling a transition from early adoption to the growth phase for Nasodine Nasal Spray. The company has disc...
Firebrick Pharma Revenue Slides as Auditor Flags Going-Concern Risk
Feb 24, 2026
Firebrick Pharma has reported a sharp fall in half-year revenue to A$63,267 for the period ended 31 December 2025, down nearly 68% from a year earlier, while narrowing its after-tax loss to A$1.26 million, a 12.7% improvement. Net tangible assets ...
Firebrick Pharma Issues 1 Million Unlisted Options to Support Capital Structure
Feb 11, 2026
Firebrick Pharma Limited has issued 1,000,000 unlisted options exercisable at $0.15 and expiring on 10 February 2030. The options, which form part of previously announced transactions and are not intended to be quoted on the ASX, represent a furth...
Firebrick Pharma Plans Issue of 1 Million Unlisted Options
Feb 9, 2026
Firebrick Pharma Limited has notified the ASX of a proposed issue of up to 1,000,000 unlisted options as part of a placement or similar capital-raising mechanism. The options will be exercisable at $0.15 and are scheduled to expire on 10 February ...
Firebrick Pharma adds seasoned North American director to drive global Nasodine growth
Feb 9, 2026
Firebrick Pharma has appointed North America-based executive Al Moghaddam as a Non-Executive Director, effective 1 March 2026, following an international search to fill a board vacancy. The company will grant him 1,000,000 options with a four-year...
Firebrick Pharma Expands Nasodine Range and International Footprint as Sales and Cost Discipline Improve
Jan 27, 2026
Firebrick Pharma reported solid operational progress in the December 2025 quarter, highlighted by the first expansion of its Nasodine product range with the Nasodine Throat Spray moving into commercial manufacturing, securing Australian approval f...
Firebrick Pharma Secures First Fiji Order for Nasodine Throat Spray
Jan 21, 2026
Firebrick Pharma has secured an initial order for 216 units of its newly launched Nasodine Throat Spray from Fiji and South Pacific licensee Makans Ltd, marking the product’s entry into the Fiji market shortly after its rollout in Singapore....
Firebrick Pharma Clears Key Regulatory Hurdle for Nasodine in Philippine Market
Jan 11, 2026
Firebrick Pharma has confirmed that the registration process for its Nasodine Nasal Spray in the Philippines has advanced, with the country’s Food and Drug Administration accepting the product dossier following pre-assessment and commencing ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.